Tumors of the Central Nervous System in Children and Adolescents

被引:30
|
作者
Fruehwald, Michael C. [1 ]
Rutkowski, Stefan [2 ]
机构
[1] I Klin Kinder & Jugendliche, Klinikum Augsburg, D-86156 Augsburg, Germany
[2] Univ Klinikum Hamburg Eppendorf, Klin Padiatr Hamatol & Onkol, Hamburg, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2011年 / 108卷 / 22期
关键词
TRIALS HIT 88/89; CHILDHOOD; MEDULLOBLASTOMA; CHEMOTHERAPY; RADIOTHERAPY; GLIOMAS;
D O I
10.3238/arztebl.2011.0390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multimodal treatment approaches for children with tumors of the central nervous system (CNS) have markedly contributed to improved survival. Before 1970, the survival rate among children with medulloblastoma, the most common malignant CNS tumor in children, was about 20%. At present, in contrast, cure can be achieved in more than 75% of children with a favorable constellation of risk factors. In this review article for clinicians, we give an overview of the current understanding of the pathology, presenting manifestations, early diagnosis, and treatment of CNS tumors in children and adolescents. Methods: We report the research findings of the German Treatment Network "HIT" and selectively review the pertinent literature. Results: Treatment-optimizing clinical trials have improved survival from all types of CNS tumors in children and adolescents. Biological features of the tumors now serve as the basis for improved stratification for multimodal, risk-adapted treatment. Targeted biological strategies are being developed. Difficulties remain, however, in the care of infants with CNS tumors and in the treatment of metastatic disease, tumors of certain histological types, and tumors in certain anatomical sites. Many of the affected children suffer from late effects of their disease and its treatment that can irreversibly impair their development. Conclusion: Children with a suspected or confirmed diagnosis of brain tumor should be referred early to a center with the relevant experience. Standardized diagnostic and therapeutic methods have markedly improved the chance of cure. Current research on molecular signaling pathways seems likely to lead to the development of new treatments, particularly for tumors currently associated with lower rates of survival. The long-term side effects of treatment must be systematically monitored so that they can be avoided in future, and so that appropriate support measures can be provided to the affected children.
引用
收藏
页码:390 / U25
页数:10
相关论文
共 50 条
  • [31] Trends in tumors in the central nervous system in elderly in Denmark, 2008-2012
    Dahlrot, Rikke H.
    Poulsen, Frantz R.
    Nguyen, Nina N. T. T.
    Kristensen, Bjarne W.
    Hansen, Steinbjorn
    Holm, Niels V.
    ACTA ONCOLOGICA, 2016, 55 : 91 - 97
  • [32] A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics
    Yao, Bing
    Wang, Hongying
    Wu, Xiaomei
    Wang, Chenyu
    Tang, Tao
    An, Wenxiu
    Zhu, Bo
    BMC CANCER, 2024, 24 (01)
  • [33] Central Nervous System Tumors in Adolescents and Young Adults: An Epidemiological Study from Jordan
    AlMuhaisen, GhadeerHayel
    Al-Tarawneh, Bushra
    Al-Hussaini, Maysa
    NEUROEPIDEMIOLOGY, 2020, 54 (04) : 326 - 333
  • [34] SEQUENCING OF LOCAL THERAPY AFFECTS THE PATTERN OF TREATMENT FAILURE AND SURVIVAL IN CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMORS OF THE CENTRAL NERVOUS SYSTEM
    Panandiker, Atmaram S. Pai
    Merchant, Thomas E.
    Beltran, Chris
    Wu, Shengjie
    Sharma, Shelly
    Boop, Frederick A.
    Jenkins, Jesse J.
    Helton, Kathleen J.
    Wright, Karen D.
    Broniscer, Alberto
    Kun, Larry E.
    Gajjar, Amar
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 1756 - 1763
  • [35] Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma
    Osorio, Diana S.
    Finlay, Jonathan L.
    Dhall, Girish
    Goldman, Stewart
    Eisenstat, David
    Brown, Robert J.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (09) : E100 - E102
  • [36] Epidemiological survey of central nervous system germ cell tumors in Canadian children
    D. Keene
    D. Johnston
    D. Strother
    C. Fryer
    A. S. Carret
    B. Crooks
    D. Eisenstat
    A. Moghrabi
    B. Wilson
    J. Brossard
    C. Mpofu
    I. Odame
    S. Zelcer
    M. Silva
    Y. Samson
    J. Hand
    E. Bouffet
    Journal of Neuro-Oncology, 2007, 82 : 289 - 295
  • [37] Epidemiological survey of central nervous system germ cell tumors in Canadian children
    Keene, D.
    Johnston, D.
    Strother, D.
    Fryer, C.
    Carret, A. S.
    Crooks, B.
    Eisenstat, D.
    Moghrabi, A.
    Wilson, B.
    Brossard, J.
    Mpofu, C.
    Odame, I.
    Zelcer, S.
    Silva, M.
    Samson, Y.
    Hand, J.
    Bouffet, E.
    JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (03) : 289 - 295
  • [38] Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility
    Cabanas, Ricardo
    Saurez, Giselle
    Alert, Jose
    Reyes, Adnolys
    Valdes, Jose
    Caridad Gonzalez, Maria
    Luis Pedrayes, Jorge
    Valle, Luis
    Infante, Mariela
    Avila, Melba
    Herrera, Raisa
    Hechavarria, Ernesto
    Rios, Marta
    Fernandez, Aymara
    Lorenzo Luaces, Patricia
    Crombet Ramos, Tania
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2014, 29 (04) : 173 - 178
  • [39] Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience
    Kirkman, Matthew A.
    Hayward, Richard
    Phipps, Kim
    Aquilina, Kristian
    CHILDS NERVOUS SYSTEM, 2018, 34 (11) : 2259 - 2267
  • [40] The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors
    Peruzzi, Pierpaolo
    Valdes, Pablo Q.
    Aghi, Manish K.
    Berger, Mitchel
    Chiocca, Ennio Antonio
    Golby, Alexandra J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (01) : 63 - 75